Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd

Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd, is the medical director of the Thoracic Cancer Program, and associate executive director at AdventHealth Cancer Institute.

Articles

Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer

February 2nd 2025

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd

November 4th 2024

Dr Mekhail discusses the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma.

Advancement in Treating Uncommon EGFR Mutations: Key Takeaways

January 3rd 2024

Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.

Investigational Avenues in Uncommon EGFR Mutations: NSCLC Treatment Insight

December 27th 2023

Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.

UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations

December 27th 2023

Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.

Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC

December 20th 2023

Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.

Optimizing Afatinib Use: Dosing Strategies and Adverse Event Management

December 20th 2023

Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.

Treatment Strategies for Uncommon EGFR Mutations in NSCLC

December 13th 2023

Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.

Navigating Uncommon EGFR Mutations in NSCLC: Challenges and Insights

December 13th 2023

Explore the complexity of uncommon EGFR mutations in lung cancer with experts discussing classifications, testing methodologies, and the necessity of comprehensive panels for accurate identification.

Standard-of-Care Approaches in EGFR-Mutant NSCLC

December 6th 2023

Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.

Navigating Uncommon Mutations in NSCLC Treatment Decisions

December 6th 2023

The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.

Non–Small Cell Lung Cancer: Streamlining Turnaround Times in Biomarker Testing

November 29th 2023

Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.

Available Methods for Biomarker Testing in Non–Small Cell Lung Cancer

November 29th 2023

Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.

Strategic Approaches to Biomarker Testing in NSCLC: Optimal Timing

November 17th 2023

Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.

Advancement in NSCLC Precision Medicine: Biomarker Testing

November 17th 2023

Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.

Dr Mekhail on Afatinib in Lung Cancers With Uncommon EGFR Mutations

April 19th 2023

Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd, discusses the prevalence of uncommon EGFR mutations in patients with lung cancer, research needs for these patients, and how the findings from the phase 3 LUX-Lung 3 and LUX-Lung 6 trials support the use of afatinib in this population.